Therefore, during noninvasive diagnosis and monitoring NASH procedure, when CK-18 or FGF-21 initially diagnoses NASH, additional steps with other biomarkers should be performed in case of false-positive results. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.